Adjuvant immune checkpoint inhibitor therapy for resected non-small-cell lung cancer: dessert, starters, or a sandwich?

Ann Oncol. 2023 Oct;34(10):829-830. doi: 10.1016/j.annonc.2023.06.010.

Authors

A John¹, S Popat²

Affiliations

¹ Lung Unit, Royal Marsden Hospital, London. Electronic address: https://twitter.com/DrAlexiusJ.
² Lung Unit, Royal Marsden Hospital, London; Section of Clinical Studies, Institute of Cancer Research, London, UK. Electronic address: sanjay.popat@rmh.nhs.uk.

PMID: 37777306
DOI: 10.1016/j.annonc.2023.06.010

No abstract available

Publication types

Editorial
Comment

MeSH terms

Adjuvants, Immunologic / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / surgery
Chemotherapy, Adjuvant
Humans
Immune Checkpoint Inhibitors / therapeutic use
Lung Neoplasms* / drug therapy
Lung Neoplasms* / surgery
Radioimmunotherapy

Substances

Immune Checkpoint Inhibitors
Adjuvants, Immunologic